Stryker update
This article was originally published in The Gray Sheet
Executive Summary
Firm expects to spend at least $50 million a year "over the next few years" to resolve issues related to three previous FDA warning letters, VP Strategy and Investor Relations Katherine Owen said during a Sept. 3 presentation at the Thomas Weisel Partners Healthcare Conference in Boston. In April, the company's biotech division received a letter citing quality system and compliance violations at its Hopkinton, Mass., facility (1"The Gray Sheet" May 5, 2008, In Brief). In 2007, the firm received warning letters stemming from inspections of its Mahwah, N.J., and Carrigtohill, Ireland, plants